Semaglutide Significantly Improves Heart Function and Weight in Obesity-Related Heart Failure

Obesity is a major risk factor for Heart Failure with Preserved Ejection Fraction (HFpEF), a condition where the heart struggles to pump blood effectively despite normal ejection fraction. While semaglutide is known for weight loss and cardiovascular benefits in other populations, there was a critical need to understand how it specifically impacts functional status and symptoms in this challenging patient population.

The study demonstrated significant improvements across multiple endpoints for the semaglutide group. Semaglutide treatment led to a substantial improvement in heart failure symptoms and physical limitations, with the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) increasing by 16.6 points compared to 8.7 points in the placebo group (a difference of 7.8 points, 95% CI 5.8 to 9.8, p<0.001). > Participants receiving semaglutide achieved a substantial mean body weight reduction of 9.4% from baseline, significantly greater than the 1.0% reduction observed in the placebo group (a difference of -8.4 percentage points, 95% CI -9.5 to -7.4, p<0.001). Furthermore, physical function improved, with a 20.3-meter increase in the 6-minute walk distance for the semaglutide group versus 1.3 meters for placebo (a difference of 18.9 meters, 95% CI 12.1 to 25.7, p<0.001). Inflammatory markers also saw a greater reduction, with C-reactive protein (CRP) decreasing by 43% in the semaglutide group compared to 16% in the placebo group (a difference of -26.1%, 95% CI -34.0 to -18.2, p<0.001).